Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): A double-blind, randomized controlled phase 3 trial
Genovese MC et al. Lancet 2018. doi: 10.1016/S0140-6736(18)31116-4
Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.